■新生儿和婴儿出现胃食管反流,表现为呕吐,反流,咳嗽.许多护理人员的抱怨始于生命的第2个月或第3个月,并在婴儿期的第6个月左右消退。由于被认为是安全和有效的药物干预措施,护理标准尚未建立,治疗选择也受到限制。基于海藻酸盐的配方,在成人中广泛使用的产品,如Gaviscon™,已被探索作为治疗胃食管反流的另一种选择。
■确定基于藻酸盐的制剂在减轻新生儿和婴儿胃食管反流症状方面的安全性和有效性。
■通过PubMed对MEDLINE的随机对照试验进行了电子搜索,HerdinPlus,Cochrane中央控制试验登记册,Scopus,和临床试验注册。搜索词是“胃食管反流,“\”酸回流,\"\"新生儿,\"\"新生儿,\"\"婴儿,\"\"宝贝,\"\"婴儿,\",和“藻酸盐”。“两位评论作者独立评估了可用的全文文章,第三位作者介入以解决讨论。
■确定了两项研究,并将其纳入本研究。由于试验的测量时间不同,未进行荟萃分析.然而,仍进行了系统审查。两项研究表明,使用基于藻酸盐的液体制剂作为干预措施,症状得到了显着改善。没有注意到显著的不良事件,使得这种治疗选择通常对于婴儿使用是安全的。
■没有足够的证据表明基于藻酸盐的制剂最终有助于减少新生儿和婴儿的胃食管反流,但初步试验显示有希望的结果。在小样本的情况下,也没有足够的数据来推断这种治疗选择的安全性。
UNASSIGNED: Neonates and infants experience gastroesophageal reflux as manifested through vomiting, reflux, and coughing. The complaint from many caregivers begins around the 2nd or 3rd month of life and subside around the 6th month of infancy. The standard of care has not been established and treatment options are limited owing to the pharmacological interventions that are deemed safe and effective. Alginate-based formulations, a widely used product in adults such as Gaviscon™, have been explored as another option to treat gastroesophageal reflux.
UNASSIGNED: To determine the safety and efficacy of alginate-based formulations in reducing symptoms of gastroesophageal reflux in neonates and infants.
UNASSIGNED: An electronic search was conducted for randomized control trials in MEDLINE via PubMed, Herdin Plus, Cochrane Central Register of Controlled Trials, SCOPUS, and Clinical Trials Registry. The search terms were \"gastroesophageal reflux,\" \"acid reflux,\" \"neonates,\" \"newborn,\" \"infants,\" \"baby,\" \"babies,\", and \"alginate.\" Two review authors independently assessed the available full text articles and a third author intervened to settle the discussion.
UNASSIGNED: Two studies were identified and included in this study. Due to the difference in the period of measurement of the trials, a meta-analysis was not pursued. However, a systematic review was still conducted. The two studies suggest a significant improvement of symptoms with alginate-based liquid formulations as intervention. No significant adverse events have been noted making this treatment option generally safe for use in infants.
UNASSIGNED: There is insufficient evidence to conclude that alginate-based formulations ultimately help decrease gastroesophageal reflux in neonates and infants, but initial trials show promising results. There is also insufficient data to conclude the safety profile of this treatment option given the small sample.